ORYZON GENOMICS, S.A. (ES0167733015) — research page
ES · es-cm-kg/XMAD/ES0167733015 · as of 2026-11-06
Identity and listing
The issuer is ORYZON GENOMICS, S.A., listed on BME Madrid under ticker ES0167733015, with ISIN ES0167733015 and LEI 95980063R15RDF29DK13. Security type, segment, sector and jurisdiction are not on the record. Listing status as of 2026-11-06 is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | ORYZON GENOMICS, S.A. | source · 2026-11-06 |
| exchange | BME Madrid | source · 2026-11-06 |
| ticker | ES0167733015 | source · 2026-11-06 |
| ISIN | ES0167733015 | source · 2026-11-06 |
| LEI | 95980063R15RDF29DK13 | source · 2026-11-09 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 18 filings in the twelve months to 2026-11-06, across 14 filing days. The median gap between filing days is 8 days. The latest filing is dated 2026-07-27, is of type Informes financieros semestrales y de auditoría / revisiones limitadas, and is 102 days before the record date. BME Madrid peers show a median cadence gap of 9 days, a median of 31.0 filings and a median latency of 8 days across 122 issuers. Sector peer figures for this market are not on the record.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 18 | 8 | 102 |
| exchange median: BME Madrid (122 issuers) | 31 | 9 | 8 |
| date | type | category | filing |
|---|---|---|---|
| 2026-07-27 | Informes financieros semestrales y de auditoría / revisiones limitadas | Informes financieros semestrales y de auditoría / revisiones limitadas | La sociedad remite información financiera del primer semestre de 2026 |
| 2026-07-21 | Total número de derechos de voto y de capital | Total número de derechos de voto y de capital | Modificación del número de derechos de voto adicionales por lealtad de la Sociedad |
| 2026-07-06 | Total número de derechos de voto y de capital | Total número de derechos de voto y de capital | Se comunica la inscripción en el Registro mercantil de la escritura de ampliación de capital. |
| 2026-07-01 | Sobre colocaciones significativas de instrumentos financieros | Sobre colocaciones significativas de instrumentos financieros | Resultado de la colocación acelerada |
| 2026-07-01 | Convocatoria de Junta o Asamblea | Convocatoria de Junta o Asamblea | ORYZON anuncia los resultados de la votación de su Junta General Ordinaria de Accionistas |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record and its location are not on the record. Auditor changes are not on the record, because this register has no lifecycle type map yet.
Events and halts
Listing, delisting, name change, domicile change and segment move are not on the record, because this register has no lifecycle type map yet. The halt flag is listed, not halted.
Orderability
The outcome is not determinable for this issuer under rule version acm-68000/es/mifid-ii-product-governance/r1, as of chapter date 2026-11-04. The chapter's orderability section carries no client categories, so the outcome cannot name its client category.
rule acm-68000/es/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
Two research houses are named on the issuer's own investor-relations page: Invest Securities (FR) and Luis Navia (ES).
| research house | analyst | source · read date |
|---|---|---|
| Invest Securities (FR) | Jamila El Bougrini Thibaut Voglimacci - Stephanopoli | issuer page · 2026-11-12 |
| Luis Navia (ES) | Luis Navia | issuer page · 2026-11-12 |
Open research
Five openly published research notes are on the record: Invest Securities on 2025-03-20, Edison Investment Research on 2022-12-16, Edison Investment Research on 2022-11-03, Edison Investment Research on 2022-07-26, and Invest Securities on 2022-06-10.
| date | publisher | note | kind |
|---|---|---|---|
| 2025-03-20 | Invest Securities | INVEST SECURITIES - STUDY ORYZON GENOMICS | issuer-sponsored |
| 2022-12-16 | Edison Investment Research | Oryzon Genomics - Lead asset granted expansion into combo therapies | issuer-sponsored |
| 2022-11-03 | Edison Investment Research | Oryzon Genomics - Clinical ramp-in in Q3, several catalysts approaching | issuer-sponsored |
| 2022-07-26 | Edison Investment Research | Oryzon Genomics - Preclinical collaboration in orphan disease | issuer-sponsored |
| 2022-06-10 | Invest Securities | INVEST SECURITIES - FLASH ORYZON GENOMICS - 10062022_EN | issuer-sponsored |
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No issuer years are sealed, and the earliest sealed date for the market and the live record start date are not on the record.
Sources
12 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.es-cm-kg.ai/events/XMAD/ES0167733015 (the disclosure lines)
- 10.4
- https://www.cnmv.es/portal/Informacion-Privilegiada/Resultado-IP?tipos=<category blob>&fechaDesde=09/11/2025&fechaHasta=09/11/2026 | https://www.cnmv.es/portal/Otra-Informacion-Relevante/Resultado-OIR?tipos=<category blob>&fechaDesde=09/11/2025&fechaHasta=09/11/2026 | https://apiweb.bolsasymercados.es/Market/v1/EQ/ShareDetailsInfo?isin=<roster ISIN> (the halt flag)
- 10.5
- https://es.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.6
- https://www.oryzon.com/en/investors/analyst-coverage (coverage)
- 10.7
- https://www.oryzon.com/sites/default/files/documents/2025-03/INVEST%20SECURITIES%20-%20STUDY%20ORYZON%20GENOMICS%20-%2025032025_EN.pdf (open research)
- 10.8
- https://www.oryzon.com/sites/default/files/documents/2022-12/Oryzon-Genomics-Lead-asset-granted-expansion-into-combo-therapies_20221216.pdf (open research)
- 10.9
- https://www.oryzon.com/sites/default/files/documents/2022-11/Oryzon-Genomics-Clinical-ramp-in-Q3-several-catalysts-approaching.pdf (open research)
- 10.10
- https://www.oryzon.com/sites/default/files/documents/2022-07/Oryzon-Genomics-Preclinical-collaboration-in-orphan-disease_0.pdf (open research)
- 10.11
- https://www.oryzon.com/sites/default/files/documents/2022-06/INVEST%20SECURITIES%20-%20FLASH%20ORYZON%20GENOMICS%20-%2010062022_EN.pdf (open research)
- 10.12
- https://mcp.es-cm-kg.ai/record/XMAD/ES0167733015 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"ES0167733015"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:c8e331e79c7216e8.